Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study
Groundbreaking ‘Whole Body’ Study will be conducted by Dr. Amy Paller at Northwestern University Up to eight subjects will have...
News
American Oncology Network’s Specialty Pharmacy Achieves ACHC Reaccreditation
American Oncology Network’s Specialty Pharmacy Achieves ACHC Reaccreditation Douglas Braun, PharmD, RPh, CSP, CPh, Vice President of Pharmacy, American Oncology...
Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON...
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), an innovator...
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
Secures new $10.0 million debt facility to replace remaining $7.85 million of Avenue Capital debt Improves cash position enabling Clene...
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
—Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash...
Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on December 19, 2024, it published an...
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable...
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for Libervant® (diazepam) Buccal Film in the United States...
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
If approved, UX111 would be the first approved therapy in the U.S. for Sanfilippo Syndrome Type ANOVATO, Calif., Dec. 19,...
Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by...
Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025
VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical...
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has...
SweetWater Brewing Announces 28th Anniversary Bash With STS9 Headlining an Immersive Jamtronica Experience
HoliBlaze Ticket Promotion Now Available for the February 22nd SweetWater Anniversary PartyATLANTA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- SweetWater Brewing...
Altimmune Added to Nasdaq Biotechnology Index
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it...
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12,...
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech...
Microbix Reports Record Product Sales for Q4 and Fiscal 2024
Full-Year Revenues of $25.4 million and Net Income of $3.5 millionMISSISSAUGA, Canada, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems...
Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
ALPHARETTA, Ga., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies...
NGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug Candidate
KdT has formed a new company to develop NGM313 in a rare disease indicationNGM Bio will receive up to $608...